Market Cap 298.21M
Revenue (ttm) 0.00
Net Income (ttm) 13.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 326,100
Avg Vol 794,258
Day's Range N/A - N/A
Shares Out 76.46M
Stochastic %K 68%
Beta 0.55
Analysts Strong Sell
Price Target $10.30

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Flo...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 845 2813
Website: www.sab.bio
Address:
777 W 41st St., Miami Beach, United States
Rassy34
Rassy34 May. 22 at 2:33 PM
$SABS Ok let's go !
0 · Reply
Cinderblocks
Cinderblocks May. 22 at 1:12 PM
$SABS https://www.tipranks.com/news/the-fly/sab-biotherapeutics-initiated-with-a-buy-at-citi-thefly-news?utm_source=webullapp.com&utm_medium=referral
0 · Reply
JTebow_CWS
JTebow_CWS May. 21 at 11:52 PM
$SABS Comes on tomorrow morning at 0900. https://youtu.be/v-nUQ7HcDbg?si=TOL1hRYD_A1XFcDB
1 · Reply
SuperGreenToday
SuperGreenToday May. 21 at 1:57 PM
$SABS Share Price: $3.64 Contract Selected: Jan 15, 2027 $4.0 Calls Buy Zone: $1.15 – $1.42 Target Zone: $2.17 – $2.65 Potential Upside: 79% ROI Time to Expiration: 238 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
DDiamond_Handz
DDiamond_Handz May. 21 at 2:58 AM
$SABS its been platforming for a while now, its time to make a move
0 · Reply
oldjimzimmer
oldjimzimmer May. 20 at 5:59 PM
$SABS I think short term goes down but still long term very bullish
0 · Reply
JTebow_CWS
JTebow_CWS May. 20 at 1:40 PM
$SABS Another big investment. https://www.bamfunds.com
2 · Reply
DARKP00L
DARKP00L May. 20 at 12:56 PM
$SABS 08:34 on May. 20 2026 Jefferies Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11 #tradeideas
0 · Reply
stockboyaisle1
stockboyaisle1 May. 20 at 10:21 AM
$SABS https://www.investing.com/news/analyst-ratings/jefferies-initiates-sab-biotherapeutics-stock-with-buy-on-diabetes-therapy-potential-93CH-4700361
0 · Reply
BioRich
BioRich May. 20 at 6:49 AM
$SABS (#11) 12) $WVE 13) $BBAI 14) $VNDA 15) $OCUL (Sorry, using this is a placeholder to see how these track over time from today. Posting late so as to not clog the boards or appear as spam. These are my actual rankings)
1 · Reply
Latest News on SABS
SAB Biotherapeutics initiated with a Buy at Citi

2026-05-22T09:15:45.000Z - 3 days ago

SAB Biotherapeutics initiated with a Buy at Citi


SAB Biotherapeutics initiated with a Buy at Jefferies

2026-05-20T09:05:51.000Z - 5 days ago

SAB Biotherapeutics initiated with a Buy at Jefferies


SAB Biotherapeutics Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 12 days ago

SAB Biotherapeutics Slides: Corporate presentation


SAB Biotherapeutics Q1 Earnings Call Highlights

May 12, 2026, 1:14 PM EDT - 13 days ago

SAB Biotherapeutics Q1 Earnings Call Highlights


SAB Biotherapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 8:30 AM EDT - 13 days ago

SAB Biotherapeutics Earnings Call Transcript: Q1 2026


SAB Biotherapeutics Earnings release: Q1 2026

May 12, 2026, 8:30 AM EDT - 13 days ago

SAB Biotherapeutics Earnings release: Q1 2026


SAB Biotherapeutics Quarterly report: Q1 2026

May 12, 2026, 8:30 AM EDT - 13 days ago

SAB Biotherapeutics Quarterly report: Q1 2026


SAB Biotherapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 25 days ago

SAB Biotherapeutics Proxy statement: Proxy filing


SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw

2026-04-02T11:26:22.000Z - 7 weeks ago

SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw


SAB Biotherapeutics Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 2 months ago

SAB Biotherapeutics Earnings release: Q4 2025


SAB Biotherapeutics Annual report: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 2 months ago

SAB Biotherapeutics Annual report: Q4 2025


SAB BIO to Participate in Upcoming Investor Conferences

Mar 2, 2026, 9:00 AM EST - 3 months ago

SAB BIO to Participate in Upcoming Investor Conferences


SAB Biotherapeutics Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 4 months ago

SAB Biotherapeutics Slides: Corporate presentation


SAB Biotherapeutics initiated with a Buy at UBS

2026-01-07T13:27:50.000Z - 4 months ago

SAB Biotherapeutics initiated with a Buy at UBS


SAB Biotherapeutics appoints David Zaccardelli as board chair

2026-01-07T13:12:17.000Z - 4 months ago

SAB Biotherapeutics appoints David Zaccardelli as board chair


SAB Biotherapeutics files $300M mixed securities shelf

2025-12-30T15:15:19.000Z - 5 months ago

SAB Biotherapeutics files $300M mixed securities shelf


SAB Biotherapeutics Registration statement: Registration Filing

Dec 29, 2025, 7:00 AM EST - 5 months ago

SAB Biotherapeutics Registration statement: Registration Filing


SAB Biotherapeutics initiated with a Buy at Guggenheim

2025-12-19T11:36:31.000Z - 5 months ago

SAB Biotherapeutics initiated with a Buy at Guggenheim


SAB Biotherapeutics Earnings release: Q3 2025

Nov 14, 2025, 4:00 PM EST - 6 months ago

SAB Biotherapeutics Earnings release: Q3 2025


SAB Biotherapeutics Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 6 months ago

SAB Biotherapeutics Quarterly report: Q3 2025


SAB Biotherapeutics Registration statement: Registration Filing

Sep 22, 2025, 8:00 AM EDT - 8 months ago

SAB Biotherapeutics Registration statement: Registration Filing


SAB BIO Highlights Data in Multiple Presentations at EASD

Sep 19, 2025, 7:24 AM EDT - 8 months ago

SAB BIO Highlights Data in Multiple Presentations at EASD


SAB Biotherapeutics Registration statement: Registration Filing

Sep 2, 2025, 8:00 AM EDT - 9 months ago

SAB Biotherapeutics Registration statement: Registration Filing


SAB Biotherapeutics Proxy statement: Proxy Filing

Aug 29, 2025, 8:00 AM EDT - 9 months ago

SAB Biotherapeutics Proxy statement: Proxy Filing


SAB Biotherapeutics Proxy statement: Proxy Filing

Aug 19, 2025, 8:00 AM EDT - 9 months ago

SAB Biotherapeutics Proxy statement: Proxy Filing


SAB Biotherapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

SAB Biotherapeutics Earnings release: Q2 2025


SAB Biotherapeutics Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

SAB Biotherapeutics Quarterly report: Q2 2025


SAB BIO Announces Oversubscribed $175 Million Private Placement

Jul 21, 2025, 7:30 AM EDT - 11 months ago

SAB BIO Announces Oversubscribed $175 Million Private Placement


SAB Biotherapeutics Proxy statement: Proxy Filing

Jun 2, 2025, 8:00 AM EDT - 1 year ago

SAB Biotherapeutics Proxy statement: Proxy Filing


SAB Biotherapeutics Earnings release: Q1 2025

May 8, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Earnings release: Q1 2025


SAB Biotherapeutics Quarterly report: Q1 2025

May 8, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Quarterly report: Q1 2025


SAB Biotherapeutics Earnings release: Q4 2024

Mar 30, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Earnings release: Q4 2024


SAB Biotherapeutics Annual report: Q4 2024

Mar 30, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Annual report: Q4 2024


SAB Biotherapeutics Slides: Corporate Presentation

Nov 19, 2024, 7:00 AM EST - 1 year ago

SAB Biotherapeutics Slides: Corporate Presentation


SAB Biotherapeutics Quarterly report: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

SAB Biotherapeutics Quarterly report: Q3 2024


SAB Biotherapeutics Earnings release: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

SAB Biotherapeutics Earnings release: Q3 2024


SAB Biotherapeutics Press release: Study Update

Sep 9, 2024, 7:00 AM EDT - 1 year ago

SAB Biotherapeutics Press release: Study Update


SAB Biotherapeutics Slides: Study Update

Sep 9, 2024, 7:00 AM EDT - 1 year ago

SAB Biotherapeutics Slides: Study Update


SAB Biotherapeutics Earnings release: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

SAB Biotherapeutics Earnings release: Q2 2024


SAB Biotherapeutics Quarterly report: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

SAB Biotherapeutics Quarterly report: Q2 2024


SAB BIO Appoints Lucy To as Chief Financial Officer

Jul 31, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Appoints Lucy To as Chief Financial Officer


SAb Biotherapeutics Rebrands as SAB BIO

Jun 20, 2024, 7:20 AM EDT - 2 years ago

SAb Biotherapeutics Rebrands as SAB BIO


SAB Biotherapeutics Proxy statement: Proxy Filing

May 30, 2024, 8:00 AM EDT - 2 years ago

SAB Biotherapeutics Proxy statement: Proxy Filing


SAB Biotherapeutics Earnings release: Q1 2024

May 20, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Earnings release: Q1 2024


SAB Biotherapeutics Quarterly report: Q1 2024

May 20, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Quarterly report: Q1 2024


SAB Biotherapeutics Provides SAB-142 Trial Update

Apr 16, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics Provides SAB-142 Trial Update


SAB Biotherapeutics to Present at INNODIA Annual Meeting

Apr 8, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics to Present at INNODIA Annual Meeting


Rassy34
Rassy34 May. 22 at 2:33 PM
$SABS Ok let's go !
0 · Reply
Cinderblocks
Cinderblocks May. 22 at 1:12 PM
$SABS https://www.tipranks.com/news/the-fly/sab-biotherapeutics-initiated-with-a-buy-at-citi-thefly-news?utm_source=webullapp.com&utm_medium=referral
0 · Reply
JTebow_CWS
JTebow_CWS May. 21 at 11:52 PM
$SABS Comes on tomorrow morning at 0900. https://youtu.be/v-nUQ7HcDbg?si=TOL1hRYD_A1XFcDB
1 · Reply
SuperGreenToday
SuperGreenToday May. 21 at 1:57 PM
$SABS Share Price: $3.64 Contract Selected: Jan 15, 2027 $4.0 Calls Buy Zone: $1.15 – $1.42 Target Zone: $2.17 – $2.65 Potential Upside: 79% ROI Time to Expiration: 238 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
DDiamond_Handz
DDiamond_Handz May. 21 at 2:58 AM
$SABS its been platforming for a while now, its time to make a move
0 · Reply
oldjimzimmer
oldjimzimmer May. 20 at 5:59 PM
$SABS I think short term goes down but still long term very bullish
0 · Reply
JTebow_CWS
JTebow_CWS May. 20 at 1:40 PM
$SABS Another big investment. https://www.bamfunds.com
2 · Reply
DARKP00L
DARKP00L May. 20 at 12:56 PM
$SABS 08:34 on May. 20 2026 Jefferies Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11 #tradeideas
0 · Reply
stockboyaisle1
stockboyaisle1 May. 20 at 10:21 AM
$SABS https://www.investing.com/news/analyst-ratings/jefferies-initiates-sab-biotherapeutics-stock-with-buy-on-diabetes-therapy-potential-93CH-4700361
0 · Reply
BioRich
BioRich May. 20 at 6:49 AM
$SABS (#11) 12) $WVE 13) $BBAI 14) $VNDA 15) $OCUL (Sorry, using this is a placeholder to see how these track over time from today. Posting late so as to not clog the boards or appear as spam. These are my actual rankings)
1 · Reply
JTebow_CWS
JTebow_CWS May. 19 at 10:39 PM
$SABS Medical/ Biotech fund buying big.
0 · Reply
Michaelsfl
Michaelsfl May. 19 at 1:55 PM
$SABS If we keep getting good news we will be looking at another RSS soon🤦
0 · Reply
JTebow_CWS
JTebow_CWS May. 19 at 1:31 AM
$SABS Perceptive Advisors a biotech fund doubled their position in less than 3 months.
0 · Reply
oldjimzimmer
oldjimzimmer May. 18 at 7:43 PM
$SABS watch the 650 SMA, 2H timeframe
0 · Reply
oldjimzimmer
oldjimzimmer May. 18 at 7:42 PM
$SABS bought more @ $3.45
1 · Reply
JTebow_CWS
JTebow_CWS May. 16 at 2:39 AM
$SABS Who’s adding by latest date.
1 · Reply
SkullInferno
SkullInferno May. 15 at 9:35 PM
$SABS on watch,,
1 · Reply
rispi
rispi May. 15 at 11:52 AM
$SABS https://ir.sab.bio/node/10386/html
1 · Reply
rispi
rispi May. 14 at 5:18 AM
$SABS yesterday I sold. See you later, may be. Glta
1 · Reply
MorganHoratio
MorganHoratio May. 14 at 1:08 AM
Here are 50 popular stocks compiled by our team; we hope this brings value to my followers.(36-40) $QUIK embedded FPGA for defense $RR service robotics for hospitality $SABS human antibody therapy platform $SERV sidewalk delivery robot fleet $SLNH behind the meter power This list represents the "Real-world Execution" of the AI era! $SERV just smashed Q1 expectations with 3X sequential growth, and its Diligent acquisition opens the massive hospital logistics market. Meanwhile, $RR’s partnership with SoundHound for voice-enabled bots is a game-changer for restaurant automation. $QUIK hitting 52-week highs further validates the surge in defense-grade eFPGA demand. I’m also holding positions here as capital rotates from "Virtual AI" into "Physical Robotics." Who has the stronger moat: the delivery fleet of $SERV or the hospitality bots of $RR? Which "AI Entity" are you betting on for 2026?
0 · Reply
Dipsetbuyer
Dipsetbuyer May. 13 at 5:31 PM
0 · Reply
BioRich
BioRich May. 13 at 3:54 PM
$XBI Is $SABS the only pure play for Hantavirus? Sympathy picks of $EBS (who just had a deal with $SABS ), $NVAX, $TNXP? Who else? (Bonus for $SABS - they are rapidly becoming a potential lead player in Type 1 Diabetes) Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply